Recombinant Complement Component 3a (C3a) | MyBioSource MBS2018643 product information

product summary

company name :

MyBioSource

product type :

protein

product name :

Recombinant Complement Component 3a (C3a)

catalog :

MBS2018643

quantity :

0.01 mg

price :

140 USD

more info or order :

MyBioSource product webpage

image

image 1 :

image 2 :

image 3 :

product information

catalog number :

MBS2018643

products type :

Recombinant Protein

products full name :

Recombinant Complement Component 3a (C3a)

products short name :

[Complement Component 3a (C3a)]

other names :

[complement C3; Complement C3; complement C3; prepro-C3; C3a anaphylatoxin; complement component C3; complement component C3a; complement component C3b; acylation-stimulating protein cleavage product; epididymis secretory sperm binding protein Li 62p; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1; complement component 3; C3 and PZP-like alpha-2-macroglobulin domain-containing protein 1Cleaved into the following 11 chains:Complement C3 beta chainComplement C3 alpha chainC3a anaphylatoxinAcylation stimulating protein; ASP; Alternative name(s):; C3adesArg]

products gene name :

[C3a]

other gene names :

[C3; C3; ASP; C3a; C3b; AHUS5; ARMD9; CPAMD1; HEL-S-62p; CPAMD1; ASP]

uniprot entry name :

CO3_HUMAN

host :

E. coli

reactivity :

Homo sapiens (Human)

purity :

> 95%

form :

20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% sarcosyl, 5%Trehalose and Proclin300

concentration :

Original Concentration: 200µg/mL

storage stability :

Storage: Avoid repeated freeze/thaw cycles. Store at 2-8ºC for one month. Aliquot and store at -80ºC for 12 months. Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

tested application :

Positive Control, Immunogen, SDS-PAGE, WB. (May be suitable for use in other assays to be determined by the end user.)

image1 heading :

Sequence Information

image2 heading :

SDS-Page

image3 heading :

Testing Data

other info1 :

Source: Prokaryotic expression. Residues: Ser672~Arg748. Tags: Two N-terminal Tags, His-tag and GST-tag. Subcellular Location: Secreted. Traits: Freeze-dried powder

other info2 :

Usage: Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex. Predicted isoelectric point: 8.2. Predicted Molecular Mass: 39.0kDa. Accurate Molecular Mass: 39kDa as determined by SDS-PAGE reducing conditions.

ncbi gi num :

115298678

ncbi acc num :

NP_000055.2

ncbi gb acc num :

NM_000064.2

uniprot acc num :

P01024

ncbi pathways :

Activation Of C3 And C5 Pathway (106412); Adaptive Immune System Pathway (366160); Alternative Complement Activation Pathway (106410); Chagas Disease (American Trypanosomiasis) Pathway (147809); Chagas Disease (American Trypanosomiasis) Pathway (147795); Class A/1 (Rhodopsin-like Receptors) Pathway (106357); Complement Activation, Classical Pathway (198823); Complement And Coagulation Cascades Pathway (198880); Complement And Coagulation Cascades Pathway (83073); Complement And Coagulation Cascades Pathway (484)

ncbi summary :

Complement component C3 plays a central role in the activation of complement system. Its activation is required for both classical and alternative complement activation pathways. A peptide (C3a) derived from the encoded protein has antimicrobial activity, so people with C3 deficiency are susceptible to bacterial infection. [provided by RefSeq, Nov 2014]

uniprot summary :

C3: C3 plays a central role in the activation of the complement system. Its processing by C3 convertase is the central reaction in both classical and alternative complement pathways. After activation C3b can bind covalently, via its reactive thioester, to cell surface carbohydrates or immune aggregates. Defects in C3 are the cause of complement component 3 deficiency (C3D). A rare defect of the complement classical pathway. Patients develop recurrent, severe, pyogenic infections because of ineffective opsonization of pathogens. Some patients may also develop autoimmune disorders, such as arthralgia and vasculitic rashes, lupus-like syndrome and membranoproliferative glomerulonephritis. Genetic variation in C3 is associated with susceptibility to age-related macular degeneration type 9 (ARMD9). ARMD is a multifactorial eye disease and the most common cause of irreversible vision loss in the developed world. In most patients, the disease is manifest as ophthalmoscopically visible yellowish accumulations of protein and lipid that lie beneath the retinal pigment epithelium and within an elastin- containing structure known as Bruch membrane. Defects in C3 are a cause of susceptibility to hemolytic uremic syndrome atypical type 5 (AHUS5). An atypical form of hemolytic uremic syndrome. It is a complex genetic disease characterized by microangiopathic hemolytic anemia, thrombocytopenia, renal failure and absence of episodes of enterocolitis and diarrhea. In contrast to typical hemolytic uremic syndrome, atypical forms have a poorer prognosis, with higher death rates and frequent progression to end-stage renal disease. Susceptibility to the development of atypical hemolytic uremic syndrome can be conferred by mutations in various components of or regulatory factors in the complement cascade system. Other genes may play a role in modifying the phenotype. Increased levels of C3 and its cleavage product ASP, are associated with obesity, diabetes and coronary heart disease. Short-term endurance training reduces baseline ASP levels and subsequently fat storage. Protein type: Secreted; Secreted, signal peptide; Inhibitor. Chromosomal Location of Human Ortholog: 19p13.3-p13.2. Cellular Component: extracellular space; extracellular region; plasma membrane. Molecular Function: protein binding; endopeptidase inhibitor activity; C5L2 anaphylatoxin chemotactic receptor binding; receptor binding. Biological Process: regulation of immune response; complement activation, alternative pathway; signal transduction; fatty acid metabolic process; complement activation; G-protein coupled receptor protein signaling pathway; positive regulation of angiogenesis; positive regulation of activation of membrane attack complex; positive regulation of type IIa hypersensitivity; positive regulation of G-protein coupled receptor protein signaling pathway; regulation of complement activation; innate immune response; immune response; positive regulation of protein amino acid phosphorylation; inflammatory response; complement activation, classical pathway. Disease: Complement Component 3 Deficiency, Autosomal Recessive; Hemolytic Uremic Syndrome, Atypical, Susceptibility To, 5; Macular Degeneration, Age-related, 9

size1 :

0.01 mg

price1 :

140 USD

size2 :

0.05 mg

price2 :

260

size3 :

0.1 mg

price3 :

400

size4 :

0.2 mg

price4 :

495

size5 :

0.5 mg

price5 :

955

size6 :

1 mg

price6 :

1415

more info or order :

MyBioSource product webpage